Pharmaceutical Composition Comprising Ruxolitinib

A solid pharmaceutical formulation of ruxolitinib with a water-soluble polymer addresses solubility and stability issues, enhancing dissolution rates and chemical stability, thus extending shelf life.

SA1120256745A1Pending Publication Date: 2026-10-05ZHEJIANG KISUN PHARMACEUTICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
SA1120256745
Authority / Receiving Office
SA · SA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-15
Filing Date
2025-09-14
Publication Date
2026-10-05

AI Technical Summary

Technical Problem

Existing pharmaceutical formulations of ruxolitinib, particularly in its free base form, face challenges in maintaining sufficient solubility and stability, especially under standard storage conditions, which can affect its efficacy and shelf life.

Method used

Formulating ruxolitinib in a solid pharmaceutical formulation with a water-soluble polymer, such as hydroxypropyl cellulose, molecularly dispersed or as a solid solution, to enhance solubility, and using specific preparation processes to ensure mechanical stability and controlled release.

Benefits of technology

The formulation significantly improves solubility and stability of ruxolitinib, ensuring higher dissolution rates and enhanced chemical stability under accelerated storage conditions, thereby extending its shelf life and maintaining drug quality.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a solid pharmaceutical formulation for oral administration, containing ruxolitinib as the active pharmaceutical ingredient, where ruxolitinib is present in its free base form. Furthermore, the present invention relates to the process of preparing the pharmaceutical formulation according to the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

In this context, the term "stability" is understood according to the definition established by the Association for Pharmaceutical Manufacturing Technologists (APV), which defines "stability" as the quality of a drug that conforms to specifications until the end of its shelf life as defined by the manufacturer. Therefore, drug quality is determined by the content and purity of the active ingredient, as well as its sensory, physical, chemical, and microbiological properties. The active ingredient content must remain at least 90% of the declared value until the end of the shelf life. The pharmaceutical formulation should preferably be stored according to the present invention at a temperature of 30°C ± 2°C and a relative humidity of 65% ± 5% (see the relevant committee). For registered medicinal products (CPMP), "Guidelines on Stability Testing: Stability Testing of Active Ingredients and Related Finished Products," CPMP / QWP / 122 / 02, Rev. 1 (correction dated 17 December 2003), the stability or shelf life should be at least one year, preferably at least two years, preferably at least three years, preferably at least 3.5 years, preferably at least four years, preferably at least 4.5 years, and preferably at least five years. Furthermore, the pharmaceutical formulation should preferably be in accordance with the present invention at a temperature of 30°C ± 2°C and a relative humidity of 65% ± 5% (see the Committee on Registered Medicinal Products (CPMP), "Stability Testing Guidelines: Stability Testing of Existing Active Ingredients and Related Finished Products"). (CPMP / QWP / 122 / 02, Rev. 1 corrected on December 17, 2003), stability or shelf life of up to one year, preferably up to two years, ideally up to three years, ideally up to 3.5 years, ideally up to four years, ideally up to 4.5 years, ideally up to five years. As previously mentioned, the present invention relates to a solid pharmaceutical formulation for oral administration, containing ruxolitinib as the active pharmaceutical ingredient, where ruxolitinib exists in its free base form. This means that all ruxolitinib in the formulation is in its free base form. The pharmaceutical formulation may be formulated according to the invention to release ruxolitinib immediately, modified, controlled, sustained, prolonged, extended, or delayed. However, according to one of the preferred models of the present invention, the pharmaceutical formulation is an immediate-release formulation. Pharmaceutical formulations with sustained, prolonged, extended, or delayed release are well-known in the previous technique and, including their preparation, fall within the general knowledge of an experienced person. In addition to the free base roxolitinib, the pharmaceutical formulation under the invention may contain one or more active pharmaceutical ingredients. However, according to another preferred model of the present invention, roxolitinib is the only active pharmaceutical ingredient in the formulation. In particular, the solubility of the free base roxolitinib can be improved if the formulation contains a water-soluble polymer. Accordingly, and in accordance with one of the preferred models for the present invention, the pharmaceutical formulation contains the free base roxolitinib mixed with a water-soluble polymer. According to one of the preferred models for the present invention, water-soluble polymers are defined as those polymers of which at least 1.0 g, and preferably 2.0 g, dissolves in 100 g of water at 25 °C and pH 7. The solubility of the free ruxolitinib base can be further improved if the innovative formulation includes a water-soluble polymer in which the free ruxolitinib base is distributed. Therefore, according to another preferred model for the present invention, the pharmaceutical formulation contains the free ruxolitinib base distributed in a water-soluble polymer. The solubility of the free ruxolitinib base can be further improved if the innovative formulation contains a water-soluble polymer in which the free ruxolitinib base is molecularly dispersed. Therefore, according to another preferred model for the present invention, the pharmaceutical formulation contains the free ruxolitinib base molecularly dispersed in a water-soluble polymer. Furthermore, the solubility of the free base roxolitinib can be further improved if the innovative formulation contains the free base roxolitinib as a solid solution in a water-soluble polymer. Therefore, according to another preferred model for the present invention, the pharmaceutical formulation contains the free base roxolitinib as a solid solution in a water-soluble polymer. According to another preferred model for the present invention, the invented pharmaceutical formulation is prepared through a process that includes the following steps: Dissolving the free base of ruxolitinib and a water-soluble polymer in a solvent to obtain a solution, and - Remove the solvent from the aforementioned solution. The innovative pharmaceutical formulation, prepared following the steps outlined, ensures sufficient solubility of the free ruxolitinib base. Organic solvents such as alcohols, water, or a combination of both can be used. For example, a free ruxolitinib base / water-soluble polymer solution can be obtained by dissolving the free ruxolitinib base in ethanol, then dissolving the water-soluble polymer in water, mixing the two solutions to obtain a final solution, and finally removing the solvent. According to another preferred model for the present invention, the water-soluble polymer is chosen from the group consisting of hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC), methyl cellulose (MC), and hydroxyethyl methyl cellulose. (HEMC), Sodium Carboxymethyl Cellulose (CMC), Hydroxyethyl Carboxymethyl Cellulose (HECMC), Hydroxypropyl Carboxymethyl Cellulose (HPCMC), Hydroxypropyl Methyl Cellulose Acetate Succinate, Cellulose Acetate Trimellitate, Acrylic and Methacrylic Polymers and their Copolymers, Methacrylic Acid-Methyl Methacrylate Copolymer, Polyaminoalkyl Methacrylate-Methacrylate Ester Copolymer, Dimethylaminoethyl Methacrylate-Butyl Methacrylate-Methyl Methacrylate Copolymer, Vinylpyrrolidone-Vinyl Acetate Copolymer, Methylphenyl Ether-Malic Acid Copolymer, Polyethylene Glycol-Caprolactam-Vinylpyrrolidone Copolymer. These water-soluble polymers can significantly increase the solubility of the free base roxolitinib and can also act as a binder to provide the innovative pharmaceutical formulation with sufficient mechanical stability. Hydroxypropyl cellulose (HPC), in particular, is a preferred water-soluble polymer for the present invention. In another preferred model, the pharmaceutical formulation is free of cellulose ester derivatives, nitrogenous polymers, and polymers with unsaturated bonds. The use of these polymers is not recommended, as they may negatively affect solubility and stability. According to another preferred model for the present invention, the weight ratio of the free ruxolitinib base and the water-soluble polymer in the formulation is between 2.0 and 0.1. According to another preferred model for the present invention, the pharmaceutical formulation also includes at least one pharmaceutically acceptable auxiliary substance that may be chosen from among, for example, thinners, binders, dispersants, lubricants, and slip-aids. Thinners are fillers used to increase the overall volume of a pharmaceutical formulation. By combining a thinner with the free base roxolitinib, the final product is given the appropriate weight and volume to facilitate production and distribution. The pharmaceutical formulation of the present invention should preferably contain at least one diluent. Thinners should ideally be used at concentrations between 15% and 95%, and preferably between 50% and 90% of the total weight of the compound. Examples of suitable thinners used according to the present invention include microcrystalline cellulose and lactose monohydrate. In one of the preferred models of the present invention, the diluents used are microcrystalline cellulose, lactose monohydrate, or a mixture of both. The pharmaceutical formulation for the present invention may contain a binder. Binders ensure that pharmaceutical formulations possess the required mechanical strength. Binders suitable for use in accordance with the present invention include povidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and sodium carboxymethyl cellulose. Binders should ideally be used at a concentration between 1% and 20% of the total weight of the formulation. As explained above, the water-soluble polymer that the innovative formulation could contain could indeed have a bonding function. The pharmaceutical formulation for the present invention may, optionally, contain a dispersant. Dispersants are added to the pharmaceutical formulation to facilitate its dispersal into smaller particles in an aqueous environment, thereby increasing the available surface area and accelerating the release of the active substance. Suitable examples of dispersants used in the present invention include crospovidone, sodium starch glycolate, croscarmellose sodium, and mixtures thereof. Dispersants should ideally be used at a concentration of 1% to 25% of the total weight of the formulation. Sodium starch glycolate is a preferred dispersant in this context, at a concentration of 1% to 5% of the total weight of the formulation. The pharmaceutical formulation described in the present invention may contain a lubricant. Lubricants are generally used to reduce sliding friction, and in particular to reduce friction at the interface between the mixture to be encapsulated and the dosing apparatus of a encapsulating machine. Suitable lubricants for use in the present invention include magnesium stearate, stearic acid, glyceryl behenate, hydrogenated vegetable oils, talc, and glyceryl fumarate. Magnesium stearate is the preferred lubricant in the present invention. The preferred lubricant should be used at a concentration between 0.01% and 5% of the total weight of the formulation, with 0.01% to 0.05% being optimal. The pharmaceutical formulation of the invention may also contain a flow-enhancing agent. These substances improve the product's flowability by reducing friction between molecules. A suitable example is colloidal silicon dioxide. The pharmaceutical formulation, according to the present invention, is a solid substance and may therefore be, for example, in the form of a tablet, capsule, pill, granule, powder, etc. However, according to one of the preferred forms of the present invention, the pharmaceutical formulation is a tablet, specifically a filmless tablet. According to another preferred model of the present invention, the pharmaceutical formulation is povidone-free. This means that the formulation contains less than 0.1% by weight, or better yet less than 0.01% by weight, of povidone, or ideally no povidone at all, based on the total weight of the formulation. The absence of povidone in the formulation has been found to improve the stability of the free base ruxolitinib. According to another preferred model for the present invention, the pharmaceutical formulation contains the free ruxolitinib base in the range of 2 mg to 50 mg, in particular 5 mg, 10 mg, 15 mg, 20 mg or 25 mg of the free ruxolitinib base. The present invention also relates to the process of preparing a pharmaceutical formulation according to the invention, which includes the following steps: a) Dissolve the free base of roxolitinib in a solvent, preferably alcohol, water, or a mixture of both, to obtain a solution; b) Apply this solution to at least one pharmaceutically acceptable adjuvant to obtain a wettable adjuvant; c) Drying the wet auxiliary material. According to a preferred model of the present invention process, step a) also involves dissolving a water-soluble polymer in the solvent or solution. According to another preferred model of the present invention's process, the process in step b) involves the granulation of at least one pharmaceutically acceptable substance to obtain granules by means of the solution in step a) as the granulating liquid, and is characterized in step c) by the drying of the resulting granules. According to another preferred model for the present invention process in step b) the solution is placed on a fluidized bed of at least one pharmaceutically acceptable excipient at an elevated temperature, preferably 30°C to 50°C. Comparative example 1 As a comparative example, Jakavi® tablets marketed in sizes of 5, 10, 15, 20 and (20+5) mg were analyzed. According to the summary of properties of the Jakavi® product, the tablets contain roxolitinib in the form of the phosphate salt (for example, the 20 mg tablets contain 20 mg of roxolitinib (free base) in the form of the phosphate salt) in addition to microcrystalline cellulose, magnesium stearate, colloidal anhydrous silica, sodium starch glycolate, povidone, hydroxypropyl cellulose, and lactose monohydrate as pharmaceutical excipients. The in vitro dissolution rate of roxolitinib of the tablets mentioned was analyzed using the paddle method (device 2) in accordance with the provisions of the European Pharmacopoeia Eur.Ph. (European Pharmacopoeia, 8th edition, 7th supplement, 2.9.3 ^dissolution test for solid oral dosage forms", p. 7367-7375 (German version)) at 50 rpm in 900 ml of buffer solution at 37°C at pH values ​​of 1.2 (hydrochloric acid solution), 4.5 (sodium acetate buffer solution) and 6.8 (phosphoric acid buffer solution). The results of the melting tests are shown in the following tables, where the infinite value data corresponds to stirring at 150 rpm for 15 minutes after the 45-minute time point. Table 1: Average dissolution values ​​for Jakavi® 5 mg tablets at different pH values ​​(Volume 900 mL; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation) Time [Accurate] pH 1.2 pH 4.5 pH 6.8 5 86(13.0) 73(0.8) 56(10.2) 10 95(4.8) 89(1.1) 78(0.7) 15 97(3.1) 93(1.1) 85(0.7) 20 98(2.6) 94(1.1) 88(1.7) 30 99(1.5) 95(1.1) 90(2.6) 45 100(1.0) 96(1.2) 91(2.5) The infinite value 101(0.6) 101(0.0) 100(0.0) Table 2: Average dissolution values ​​for Jakavi® 10 mg tablets at different pH values ​​(Volume 900 mL; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation)). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 77(5.4) 70(3.6) 67(3.1) 10 87(2.4) 86(0.0) 84(6.5) 15 90(1.3) 89(1.1) 89(7.3) 20 92(1.1) 91(1.7) 91(7.2) 30 95(0.6) 92(1.7) 93(6.6) 45 97(0.6) 93(1.6) 94(6.4) The infinite value 102(1.0) 100(1.2) 101(1.5) Table 3: Average dissolution values ​​for Jakavi® 15 mg tablets at different pH values ​​(Volume 900 mL; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation)). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 85(5.4) 74(6.1) 66(4.0) 10 92(1.7) 86(4.4) 82(2.5) 15 94(0.6) 88(3.6) 86(2.3) 20 95(0.6) 89(3.6) 88(1.7) 30 97(0.6) 90(3.6) 90(1.1) 45 98(0.6) 91(2.9) 91(1.7) The infinite value 101(1.0) 98(0.6) 99(0.6) Table 4: Average dissolution values ​​for Jakavi® 20 mg tablets at different pH values ​​(volume 900 ml; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation) Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 83(2.5) 70(3.0) 59(2.6) 10 90(1.9) 81(2.6) 77(3.9) 15 92(1.9) 83(3.0) 82(4.3) 20 93(2.2) 85(2.5) 85(4.1) 30 94(2.2) 86(2.4) 86(4.7) 45 96(2.6) 87(2.4) 88(4.5) Infinite value 100(1.5) 96(1.0) 98(0.0) Table 5: Average dissolution values ​​for Jakavi® 20 mg + 5 mg tablets (Jakavi® 20 mg tablet and Jakavi® 5 mg tablet) at different pH values ​​(Volume 900 mL; 50 rpm; p = 3 (number of tablet pairs). Values ​​in parentheses represent RSD [%] (relative standard deviation). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 85(9.3) 59(3.5) 58(4.3) 10 91(7.3) 72(2.1) 72(2.1) 15 93(6.2) 76(2.0) 76(2.0) 20 95(5.8) 78(1.5) 77(2.0) 30 96(5.1) 80(2.2) 80(2.6) 45 98(4.8) 82(2.5) 82(2.4) The infinite value 104(2.8) 92(1.3) 92(1.1) Furthermore, the stability of Jakavi® 20 mg tablets was studied in terms of the chemical stability of roxolitinib, i.e., the original value immediately after purchase, as well as after storage in aluminum-aluminum containers under accelerated conditions at 40°C / 75% RH / 15 days or at 60°C / 75% RH / 15 days. The stability study results are shown in Table 6 below: Table 6: Stability of Jakavi® 20 mg tablets Storage conditions: Total impurities / % Original 0.2 40°C / 75% humidity / 15 days 0.22 60°C / 75% humidity / 15 days 0.62 The data presented in Table 6 were determined using high-performance liquid chromatography (HPLC) and evaluated using the area uniformity method. The HPLC process was performed according to the following criteria: High-performance liquid chromatography (HPLC), chromatography conditions: Column: Zorbax Eclipse XDB C18, 3.5 [mm (150*4.6 mm); Mobile phase: a) Water, b) Acetonitrile, linear dissolution (below) Time (minutes) A ​​(%) B (%) 0.0 85 15 4.0 70 30 12.0 50 50 25.0 10 90 25.1 15 85 30.0 85 15 Detection wavelength: 220 nanometers; Flow rate: 1.0 ml / min; Column temperature: 30 degrees Celsius; Test solvent: Acetonitrile - Water (1:1); Test concentration: 250 micrograms / ml Example 1 Roxolitinib tablets were prepared as one of the solid oral pharmaceutical formulations according to the invention, with the following formulation: Tablet component [percentage by weight] Roxolitinib free base (dihydrate) 3.4 Microcrystalline cellulose (PH101) 39.4 Lactose monohydrate 50.5 Sodium carboxymethyl starch (a) 3.0 Hydroxypropyl cellulose (HPC-L, low substitution) 2.5 colloidal silica 0.9 Magnesium stearate 0.3 Water (not present in the final product) (22) Ethanol (not present in the final product) (14.8) Total 100 These tablets (containing 5 mg, 10 mg, 15 mg, and 20 mg of the free base roxolotinib) were prepared according to a preparation process described in the present invention. The preparation of the 20 mg free base roxolotinib tablets is described below. The granulation fluid was prepared by dissolving 27.94 g of free base roxolitinib (dihydrate) in 100 g of 95% ethanol to obtain a first solution, and by dissolving 20 g of hydroxypropyl cellulose in 150 g of purified water to obtain a second solution, and by mixing the first and second solutions to obtain the granulation fluid in the form of a solution. The aforementioned granulation fluid was sprayed onto a fluidized bed of microcrystalline cellulose, lactose monohydrate, and sodium carboxymethyl starch at a spray pressure of 3.0 bar and an inlet air temperature of 40°C. After spraying the granulation fluid, the tubes were washed with 50 g of a 40% ethanol / water solution, which was also sprayed onto a fluidized bed. The resulting granules were dried in a fluidized bed at a temperature of 40°C until the loss limit reached 2.3%. The dried granules are mixed with colloidal silica, then ground, sieved, lubricated with magnesium stearate, and pressed to form tablets that have the same shape and hardness as the example tablets. The in vitro solubility rate of roxolitinib from the tablets mentioned in the invention was determined in accordance with the terms and conditions stated under item “Comparative Example 1”. The results of the solubility tests are shown in the following tables 7 to 11: Table 7: Average dissolution values ​​of 5 mg free-base roxolitinib tablets at different pH values ​​(volume 900 mL; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation)). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 100(4.6) 87(2.2) 87(2.6) 10 105(1.9) 102(2.5) 103(0.9) 15 106(1.4) 104(2.5) 106(0.5) 20 106(1.1) 105(1.6) 106(0.9) 30 106(1.1) 106(0.5) 107(1.1) 45 106(1.1) 106(0.5) 107(1.1) Infinite value 106(1.4) 108(1.8) 107(0.9) Table 8: Average dissolution values ​​of 10 mg free-base roxolitinib tablets at different pH values ​​(volume 900 mL; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation)). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 93(0.6) 88(1.1) 84(2.4) 10 101(0.6) 98(1.5) 100(1.0) 15 102(1.1) 99(1.5) 102(1.1) 20 103(0.9) 99(1.5) 102(0.6) 30 103(1.4) 100(1.0) 103(0.5) 45 103(1.4) 100(1.0) 103(0.5) Infinite value 103(1.4) 101(2.0) 103(0.0) Table 9: Average dissolution values ​​of 15 mg free-base roxolitinib tablets at different pH values ​​(volume 900 mL; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation)). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 92(4.4) 92(1.6) 87(5.3) 10 100(3.4) 100(1.0) 100(2.5) 15 101(3.1) 101(1.1) 102(1.9) 20 103(2.9) 102(1.0) 103(2.0) 30 103(2.5) 103(0.5) 103(1.4) 45 104(1.9) 104(0.5) 103(1.9) Infinite value 105(1.9) 104(0.9) 105(0.5) Table 10: Average dissolution values ​​of 20 mg free-base roxolitinib tablets at different pH values ​​(volume 900 mL; 50 rpm; p = 3 (number of tablets). Values ​​in brackets represent RSD [%] (relative standard deviation)). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 95(4.3) 91(1.1) 86(1.3) 10 101(1.5) 100(2.6) 96(1.2) 15 102(0.0) 101(2.5) 98(1.1) 20 103(0.5) 102(2.9) 98(1.1) 30 104(0.5) 102(2.4) 99(1.1) 45 104(0.5) 102(2.9) 100(1.0) Infinite value 104(0.9) 104(2.0) 102(0.6) Table 11: Average dissolution values ​​of 25 mg free-base roxolitinib tablets at different pH values ​​(volume 900 mL; 50 rpm; p = 3 (number of tablet pairs). Values ​​in brackets represent RSD [%] (relative standard deviation)). Time [minutes] pH 1.2 pH 4.5 pH 6.8 5 94(3.8) 88(4.2) 85(3.5) 10 98(2.3) 99(1.5) 98(2.0) 15 99(1.5) 100(1.0) 100(2.0) 20 100(1.5) 101(0.6) 100(1.9) 30 100(1.0) 101(0.6) 101(2.4) 45 101(1.1) 102(0.6) 101(1.9) Infinite value 102(1.1) 102(0.0) 103(0.9) Comparing the dissolution data for Comparative Example 1 with the dissolution data for the present example according to the invention reveals that the dissolution rates of the formulation according to the invention are much higher at all pH values ​​examined compared with the corresponding previous comparative examples. Furthermore, the stability of the first example tablets was studied in light of the chemical stability of roxolitinib, specifically the original value immediately after tablet preparation, as well as after storage in aluminum-aluminum cartons under accelerated conditions at 40°C / 75% RH / 15 days, or at 60°C / 75% RH / 15 days. The stability study results were determined by standardizing the peak area obtained by high-performance liquid chromatography (HPLC), and are shown in Table 12 below: The data in Table 12 were identified and evaluated using the methods described in Chapter above, "Comparative Example 1". Table 12: Stability of roxolitinib formulation with a free base at a concentration of 20 mg Storage conditions: Total impurities / % Original 0.03 40°C / 75% humidity / 15 days 0.05 60°C / 75% humidity / 15 days 0.27 Comparing the stability data for Comparative Example 1 with the stability data for Example 1 clearly shows that the stability of roxolitinib is much higher in the formulation according to the current invention. This comparison is also shown in Table 13 below. Roxolitinib free base 20 mg Jakavi® 20 mg tablets Total impurities [%] Total impurities [%] Storage conditions 0.02 0.2 Original 0.05 0.22 40°C / 75% Humidity / 15 days 0.27 0.62 60°C / 75% Humidity / 15 days

Claims

Claims1. A solid oral pharmaceutical composition comprising ruxolitinib as an active pharmaceutical ingredient wherein ruxolitinib is present in the form of its free base.

2. The pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition is an immediate release composition.

3. The pharmaceutical composition according to one of the preceding claims, characterized in that ruxolitinib is the only active pharmaceutical ingredient contained in the composition.

4. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition contains the ruxolitinib free base in admixture with a water soluble polymer.

5. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition contains the ruxolitinib free base dispersed in a water soluble polymer.

6. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition contains the ruxolitinib free base molecularly dispersed in a water soluble polymer.

7. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition contains the ruxolitinib free base as a solid solution of ruxolitinib free base in a water soluble polymer.

8. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition is prepared by means of a process that comprises the steps of- dissolving ruxolitinib free base and a water soluble polymer in a solvent to obtain a solution, and- removing the solvent from said solution.

9. The pharmaceutical composition according to one of the claims 4 to 8, characterized in that the water soluble polymer is selected from the group consisting of hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), hydroxypropylmethylcellulose (HPMC), methylcellulose (MC), hydroxyethyl methylcellulose (HEMC), sodium carboxymethylcellulose (CMC). hydroxyethylcarboxymethylcellulose (HECMC), hydroxypropyl carboxymethylcellulose (HPCMC), hydroxypropylmethycellulose acetate succinate, cellulose acetate trimellitate, acrylic and methacrylic polymers and their copolymers, methacrylic acid - methylmethacrylate copolymer, polyaminoalkyl methacrylate- methacrylic esters copolymer, dimethylaminoethyl methacrylate - butylmethacrylatemethylmethacrylatecopolymer, vinylpyrrolidone- vinyl acetate copolymer, methylvinylether- maleic acid copolymer, polyethyleneglycol- caprolactame- vinylpyrrolidone copolymer.

10. The pharmaceutical composition according to one of the preceding claims, characterized in that the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

11. The pharmaceutical composition according to one of the preceding claims, characterized in that the pharmaceutical composition is a tablet.

12. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition is free of povidone.

13. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition contains ruxolitinib free base in the range from 2 mg to 50 mg.

14. The pharmaceutical composition according to one of the preceding claims, characterized in that the composition contains 5 mg, 10 mg, 15 mg, 20 mg or 25 mg ruxolitinib free base.

15. A process for the preparation of a pharmaceutical composition according to one of the preceding claims comprising the following steps: d)dissolving ruxolitinib free base in a solvent to obtain a solution; e)applying said solution on at least one pharmaceutically acceptable excipient to obtain a wetted excipient; f)drying the wetted excipient.

16. The process according to one of the preceding claims, characterized in that step a) further comprises the dissolution of a water soluble polymer in the solvent or solution.

17. The process according to one of the preceding claims, characterized in that step b) comprises the granulation of the at least one pharmaceutically acceptable excipient to obtain a granulate by means of the solution of step a) as granulation liquid, and characterized in that step c) comprises the drying of the resultant granulate.

18. The process according to one of the preceding claims, characterized in that in step b) the solution is applied on a fluidized bed of the at least one pharmaceutically acceptable excipient at an elevated temperature.